论文信息 - Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) - 字舞流文

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

P. Sharma | M. Konopleva | Z. Estrov | J. Allison | H. Kantarjian | G. Garcia-Manero | J. Cortes | T. Kadia | F. Ravandi | Koichi Takahashi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | S. Pierce | S. Kornblau | R. Assi | S. Basu | Y. Alvarado | C. Benton | Allison M. Pike | W. Flores | P. Thompson